🔎 Trials Near Me

Home › Breast Cancer › NCT06507930

The COMPASSION Study

Recruiting

The COMPASSION Study: Applying Telehealth to Innovate and Strengthen Connections for Patients With Metastatic Breast Cancer Receiving Hospice Care

Who can join

Ages 18 and older · All sexes

Full eligibility criteria
Inclusion Criteria:

* Patient of any gender with unresectable locally advanced or metastatic breast cancer
* Eligible for in-home hospice services and referred by DFCI clinical team to in-home hospice \</= 1 week before enrollment
* Ability to conduct video or phone check-ins, even if assistance required.
* Able to provide verbal consent with a willingness to take a survey at 4-6 weeks, if medically able
* Hospice setting is within Massachusetts
* Non-English language allowed but interpreter services must be present at each meeting and will be coordinated by scheduling team
* Willingness to provide a caregiver/loved one's contact information for survey contact at 4 weeks after enrollment

Exclusion Criteria:

* Unable to provide verbal consent
* Hospice care planned outside of a home setting (note: if participants start out in a home hospice setting but later transition their hospice care to an inpatient setting, enrollment is allowed as long as they started in a home setting)
* Hospice setting outside of Massachusetts
* Individuals who are under the age of 18, as this is not a project focused on pediatric patients.

About the study

The aim of this research study is to better understand the in-home hospice experience for participants, caregivers, hospice nurses, and oncology providers by conducting telehealth check-ins between participants and caregivers and oncology care teams.

What is being tested

Sponsor: Dana-Farber Cancer Institute · Participants: 200 · Started: Sep 1, 2024

Contact the study team

Official record on ClinicalTrials.gov — NCT06507930

Locations in the U.S.

MassachusettsDana-Farber Cancer Institute, Boston

Conditions

From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.